# US 2015/0148385 A1 · Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148385 A1
- Document ID: US20150148385A1
- Status: Published application
- Kind: A1
- Application number: 14/411,811
- Filed: 2013-06-28
- Published: 2015-05-28
- Earliest claimed: 2012-06-29
- Assignees: Shionogi & Co., Ltd.
- Applicants: Shionogi & Co., Ltd.
- Inventors: Takeshi Kano; Takahiro Fukuhara; Takayuki Katsube
- Web page: https://patentgrep.com/patent/US20150148385A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; “when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.

## Claims

### Claim 1

A pharmaceutical composition for increasing platelets containing a compound having a thrombopoietin receptor agonistic activity, characterized by discontinuing administration of the pharmaceutical composition to a patient at the time point when a platelet count in the patient has increased by 2×104/μL or more from a platelet count before initiation of administration and has reached to 5×104/μL or higher.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, which is administered to a thrombocytopenia patient.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the platelet count in the patient before initiation of administration of the pharmaceutical composition is less than 5×104/μL.

### Claim 4 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the patient is scheduled to undergo invasive procedures.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the invasive procedures are elective invasive procedures.

### Claim 6 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the invasive procedures are radiofrequency ablation.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the radiofrequency ablation is performed on liver cancer.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the liver cancer is primary liver cancer.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the patient has chronic liver disease.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the chronic liver disease is caused by hepatitis B virus or hepatitis C virus.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the compound having a thrombopoietin receptor agonistic activity is (E)-3-[2,6-dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]-thiazol-2-ylcarbamoyl]-phenyl]-2-methylacrylic acid or a salt thereof.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, which is orally administered.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, which is administered at 2.0 to 4.0 mg/day as an amount of (E)-3-[2,6-dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]-thiazol-2-ylcarbamoyl]-phenyl]-2-methylacrylic acid or a salt thereof.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein a maximum administration period with once daily administration is 14 days or less.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, for promoting production of platelets before invasive procedures in thrombocytopenic patients with chronic liver disease.

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, for promoting production of platelets before elective invasive procedures in thrombocytopenic patients with chronic liver disease.

### Claim 17 (depends on 1)

The pharmaceutical composition according to claim 1, for promoting production of platelets before local therapy for primary liver cancer.

### Claim 18 (depends on 1)

The pharmaceutical composition according to claim 1, for promoting production of platelets before radiofrequency ablation for primary liver cancer.

### Claim 19 (depends on 1)

The pharmaceutical composition according to claim 1, for promoting production of platelets before various minimally invasive procedures in thrombocytopenic patients with chronic liver disease.

### Claim 20

A method for increasing platelets comprising the steps of:
administering a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity to a patient; and
discontinuing administration at the time point when a platelet count in the patient has increased by 2×104/μL or more from a platelet count before initiation of administration and has reached to 5×104/μL or higher.

### Claim 21

A compound having a thrombopoietin receptor agonistic activity for use in increasing platelets, characterized by discontinuing administration of the compound to a patient at the time point when a platelet count in the patient has increased by 2×104/μL or more from a platelet count before initiation of administration and has reached to 5×104/μL or higher.

### Claim 22

Use of a compound having a thrombopoietin receptor agonistic activity for manufacturing a medicament for increasing platelets, characterized by discontinuing administration of the medicament to a patient at the time point when a platelet count in the patient has increased by 2×104/μL or more from a platelet count before initiation of administration and has reached to 5×104/μL or higher.
